Have any questions? 706-721-6582 or cts@augusta.edu
- 4010-03-001 / ENGOT EN-6 / GOG-3031: A phase 3, randomized, double-blind, multicenter study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer (RUBY)
Clinical Trial
4010-03-001 / ENGOT EN-6 / GOG-3031: A phase 3, randomized, double-blind, multicenter study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer (RUBY)
The purposeof this study is to find out if an investigational drug called dostarlimab in combination with chemotherapy, can help delay worsening of cancer among patients.
Eligibility Criteria
- Must be a female at least 18 years of age with a histologically or cytologically proven endometrial cancer with recurrent or advanced disease. Subjects must provide adequate tumor sample at screening. Subjects may not have received neo-adjuvant/adjuvant systemic chemotherapy for primary Stage III or IV disease.
RESEARCH. INNOVATION. DISCOVERY.